Sellers compete on shipping speed and say it protects the compound. The published stability work does not support that. What actually stops a parcel is written down in customs law, with dates, and almost nobody reads it.
What shipping does, and does not do
What a laboratory uses to see damage
40°C
at 75 percent humidity,
held for six months
What actually decides it
water
residual moisture sealed into
the vial, not days in a van
ICH Q1A(R2), Stability Testing of New Drug Substances and Products
The usual pitch: every extra day in a van is another day of heat, the powder breaks down, so fast shipping protects what you get.
It sounds like science. It is on a lot of supplier pages. Almost nobody checks it, because it flatters everybody's marketing at once.
So we checked it.
Strickley and Anderson / ICH Q1A(R2)
The powder in the vial is freeze dried. That is not a packing choice. It is a preservation trick.
Take the water out of a peptide and lock what is left into a dry glassy solid, and it becomes far more stable than it was in liquid. That is the whole point of doing it.
Here is the clearest clue that it works. Scientists who study how these powders break down have to bake them to see anything happen.
| Study | Temperature they had to use |
|---|---|
| Freeze dried growth hormone | 40 and 50 degrees |
| A freeze dried growth factor | 40, 50 and 60 degrees |
| A peptide reacting with its filler | 70 degrees |
They heat it because at normal temperatures the damage is too slow to measure in a reasonable time. The harmonised guideline the industry tests against, ICH Q1A(R2), sets the accelerated condition for a drug substance at 40 degrees and 75 percent relative humidity, held for six months, and says accelerated data are there to cover short excursions in shipping. That alone should make you doubt that a few extra days in a delivery van changes much.
The same studies are clear. What mattered most was how the powder was made: what it was mixed with, how it was dried, and how much of the material sat exposed at the surface. One study found two different fillers gave twice the difference in stability.
How it was made matters enormously. Whether it took three days or nine to reach you matters very little next to that.
A supplier who talks hard about shipping speed and says nothing about how the product was made and sealed is pointing at the smaller number.
The variable that keeps coming back is not temperature. It is water. Strickley and Anderson, writing in Pharmaceutical Research in 1996, held freeze dried insulin at 35 degrees and found the degradation rate rose with the moisture the powder had absorbed, only approaching the rate seen in solution once the water content was high enough. Costantino and colleagues found aggregation tracking water uptake directly. A companion study on a model peptide found residual water driving deamidation both as a solvent and by softening the solid.
Which means the number that decides this was fixed before the parcel existed, when the vial was dried and sealed.
No published study has assayed a lyophilised peptide before and after an actual multi-day postal transit. We looked for one. There is no general figure either for how long lyophilised peptide powder stays stable at ambient temperature, because it is not one number: it depends on the peptide, the excipients and the residual moisture.
So this page will not give you a number of days, and you should distrust any seller who does.
Two fair caveats. Much of this work is on larger proteins and on peptides that are not the ones sold here, and a short peptide is not identical. And it is about degree rather than absolutes: five weeks in a hot warehouse is not three days in a van. The point is narrower. Transit is not the main variable, and it gets sold as if it were the only one.
Directive 2001/83/EC / Union Customs Code
A parcel that takes five weeks instead of three is usually not slow. It has been stopped, and in Europe being stopped is not a delivery problem.
“Habe zuvor bei anderen, teilweise aus den USA (→ so gut wie jedes mal Zollprobleme), teilweise aber auch bei anderen EU Herstellern gekauft.”
I used to buy from others, partly from the USA, where there was customs trouble almost every time, and partly from other EU sellers.
gutefrage.net
Here is the part that surprises people. There is no personal use exemption in EU medicines law. Not a narrow one, not a small quantity one. The consolidated text of Directive 2001/83/EC, which is the European code on medicinal products for human use, contains no such exemption at all.
Article 6(1) is the rule it does contain: no medicinal product may be placed on a member state's market without a marketing authorisation. The one individual patient derogation, Article 5(1), runs through a prescriber rather than a buyer. And Article 85c(1) permits selling medicines at a distance to the public only where the seller is authorised to supply medicines to the public in the member state it is selling into.
The European Commission's own Your Europe portal states plainly that there are no EU wide rules on buying prescription medicine online, and that member states differ.
So the question is never "is this allowed in Europe". It is "is this allowed where I live", and the answer changes at every border.
The customs machinery underneath is uniform even where the medicines law is not. Under Article 134(1) of the Union Customs Code a parcel is under customs supervision from the moment it enters, and remains subject to prohibitions and restrictions. Under Article 201(2), releasing it for free circulation means applying those restrictions, not just collecting the duty. Where goods cannot be released because a restriction applies, customs must dispose of them.
Article 197 of the Union Customs Code puts the cost of destroying the goods on the holder, not on the state and not on the sender.
So the worst case is not that you lose the money you spent. It is that you lose the money you spent and are then asked to pay for the disposal.
Arzneimittelgesetz / Anti-Doping Act
Germany is worth its own section because it is the largest market for this and the strictest about it, and because the rules there are commonly described in forums in a way that is not what the statute says.
Section 73(1) of the German Medicinal Products Act, the Arzneimittelgesetz, prohibits bringing in a medicinal product that requires authorisation unless it is authorised, approved or registered for the German market. German customs states the consequence on its own guidance pages in plain words: private individuals may not obtain medicines from abroad by post or courier.
Two details decide most cases, and both run against the buyer.
Section 74(1) AMG gives customs the power to stop the consignment and report it. Customs does not make the medicines call itself: classification goes to the Land medicines authority, with customs acting in administrative assistance, a division of labour the Landesdirektion Sachsen sets out on its own pages.
The allowance quoted constantly in European peptide threads applies to medicines carried in personally on entry, not to parcels. It is an interpretation by the supreme Land health authorities, not a postal exemption.
The narrow intra-EU exception that does exist for private sending, at section 73(2) no. 6a AMG, carries a condition that forecloses this category entirely: the product has to be authorised. An unapproved research chemical cannot satisfy it.
Bringing medicines in contrary to section 73(1) is an administrative offence carrying a fine of up to 25,000 euros. Bringing in a falsified medicine or falsified active substance is a criminal offence punishable by up to a year's imprisonment or a fine.
And there is a second statute most buyers have never heard of. Germany's Anti-Doping Act reaches the buyer rather than only the seller: acquiring, possessing or bringing in a listed doping agent in a not insignificant quantity is an offence carrying up to three years' imprisonment or a fine, and attempt is punishable. Its annex names by example the exact compounds sold as research peptides, including CJC-1295, Ipamorelin, GHRP-2, GHRP-6, Hexarelin and MK-677.
German customs has published a dated account. In a press release of 10 December, two parcels from India and South Korea were checked during postal clearance and stopped.
No administrative penalty was imposed. The choice of what happened to the goods then fell to the recipient: re-export, or destruction.
That is the ordinary outcome, and it is worth knowing because it is neither the disaster nor the free pass that forum threads describe.
Serbian Customs Administration
Serbia's Law on Medicines and Medical Devices bans trade in a medicine over the internet and by post outright, as two separate prohibitions in the same article. Where an unauthorised medicine is allowed in, the applicant is never the patient: the request goes to the Agency from a wholesale licence holder. There is a research route, and it also runs through the Agency, limited to the quantity the research needs.
The Serbian Customs Administration tells the public directly that medicines cannot be ordered into Serbia by post.
The procedure, if it happens, is worth knowing in advance:
Port of Cincinnati / Import Alert 66-41
None of the following applies to a European address. It is here because it is the only part of this subject where a government publishes its own numbers, and because two claims that circulate widely in this market turn out to be wrong when you open the document.
In a local media release dated 31 March 2026, US Customs and Border Protection's Port of Cincinnati said officers seized about 5,000 individual shipments of peptides in a scheme traced to a shipper in China, identifying over 300 master carton smuggling attempts, in a pattern first noticed in December 2025 and with seizures running through 25 March. Every shipment in that case was, in CBP's words, mis-manifested as something other than what it contained. The release names seven compounds: retatrutide, semaglutide and tirzepatide, which it calls GLP-1 medications, plus MOTS-C, TB10, semax and cagrilintide. That list ends with the words "and others", so it is a sample of what was seized rather than an inventory.
It names no importer, no company, no arrest and no charge. It gives no weight, no value and no vial count. It says nothing about what was done with the goods afterwards, and nothing about Europe.
It also prints "TB10", which is not a name anything is commonly sold under, and does not explain it. We have left it as printed rather than guessing what was meant.
The instrument behind that kind of stop is FDA Import Alert 66-41, "Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S." It is not law. FDA states it is internal guidance to its own field staff. What it does is authorise FDA divisions to detain listed goods without opening or testing them.
Its practical effect is the part worth understanding. Detention without physical examination reverses the usual burden: FDA does not have to show the parcel is in breach, the importer has to produce evidence that it is not.
That personal use protects a small private parcel. FDA states the personal use enforcement discretion generally does not apply to products of this kind.
That twelve peptides were added to the alert in 2025. This is repeated across vendor content hubs. We read the Red List. Twelve entries carry the peptide product code, and every one of them was published between 2012 and 2020. Of the 849 entries published in 2025, none names a peptide anywhere in its firm name, product code or description.
We can refute that claim for this alert. We did not open every other FDA import alert, so we are not saying nothing was added anywhere.
Named peptide sellers do sit on that list. CanLab Research of Montreal has been listed for PT-141 since 21 March 2020, and FDA's published reasoning rests substantially on the firm's own social media posts. Sbs Genetech of Beijing carries four peptide entries, all published in August 2012. GL Biochem of Shanghai is listed for Melanotan I and II and for dermorphin.
One detail matters more than the rest for anyone who reads "research use only" as a shield. FDA's stated reason for two of those listings is the research framing itself: the agency's position is that the goods enter described as non-human research material and are promoted for human use.
Union Customs Code / Regulation 2026/382
A slow shipment does not just delay a problem. It can quietly turn money you could have got back into money you cannot, because card disputes have deadlines and five weeks of not knowing can run past them.
| What might have happened | What it means for you |
|---|---|
| Just slow | Nothing. It arrives. |
| Lost in transit | The seller's published terms decide this, if they have any. Read them before you order, not after. |
| Stopped at the border | You may get a letter. In Germany the classification goes to a medicines authority; in Serbia you have thirty days to answer. |
| Never sent | A payment dispute, and that window closes. |
Waiting is the one response that is wrong in three of these four cases.
The cost side has also changed and most forum advice predates it. The EU's import VAT exemption for consignments under 22 euros ended on 1 July 2021, so VAT is due on a commercial parcel of any value. The 150 euro customs duty relief for low value consignments has since been abolished outright by Council Regulation (EU) 2026/382 of 11 February 2026, with a flat duty applying from 1 July 2026. Under Article 77 of the Union Customs Code the declarant is the debtor for import duty, which is how the bill reaches the person receiving the parcel.
Speed is the thing sellers compete on because it is the thing they control. It is close to the least important variable on this page.
Whether three days is fresher than nine. No published study has assayed a lyophilised peptide before and after an actual multi-day postal transit. Nobody claiming their shipping speed protects the compound is citing a measurement, because there is not one to cite.
None of this is legal advice and we are not lawyers. Everything above is what the named documents say, with dates, so that you can open them yourself. If your own position matters to you, the person to ask is a lawyer in your country, not a seller and not a forum.
One page on what shipping does and does not do to a peptide, and the two questions to ask any seller about it.
You are on the list.
The sheet comes by email, as one page you can print.
It follows once our list is live, and nothing else is sent. We do not sell peptides and we are not going to email you about any.
One email with the sheet. Unsubscribe in one click. We do not share addresses.
Before you go
One sheet, in plain language, that you can run on any seller in any country. One column filled in from a published certificate, and one left empty for the seller you already have open.
You are on the list.
The sheet comes by email, as one page you can print.
Nothing else follows it. We do not sell peptides and we are not going to email you about any.
One email with the sheet. Unsubscribe in one click. We do not share addresses.